RE: Up she goes28 Jan 2021 21:04
Hi Furion, Hi Clark, Hi Pineapple,
I believe we have a better, Quality Product range than NCYT, and yes I believe, we can do better than NCYT.
NCYT have done very well, helped by the fact that they were first to market launch, well ahead of us at GDR.
NCYT have showed us the way.
Today’s RNS confirming our Distributor Agreement with BC is a Game changer for us!
I believe that GDR Mcap is potentially worth £300 mil Mcap, based on projected Sales and Profit.
I expect GDR to sell 50,000 RT-PCR Test units/day, at £10 per Test = £500,000 per day revenue at 60% profit margin = £300,000 per day profit.
Working on a 5 day week = 5 x £300,000 = £1,500,000 profit per week.
£1,500,000 x 50 wks per year = £75,000,000 profit per year.
Using a standard multiple of 4 for valuation = 4 x £75,000,000 = Mcap of £300,000,000
Mcap of £300,000,000 divided by 64,000,000 shares = a potential SP of £4.68p
I am OK with a potential SP of £4.68p, and this valuation does not take into consideration a valuation of our POC; HCV; DOD OR AIHL etc
Testing is going to be needed for many, many years ahead.
Great Times Ahead for All GDR Investors !